TEMPE, Ariz., March 7, 2007 (PRIME NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that it will release financial and operating results for the year ending December 31, 2006, on Wednesday, March 14, 2007.
Management will host a conference call and webcast the same day at 4:30 PM EDT (1:30 PM MT/PDT). The call may be accessed at 866-761-0749 (domestic) or 617-614-2707 (international), with access code 11208335, or by logging onto the Investors section of the Company's website, www.orthologic.com.
A replay will be available beginning March 14, 2007, at 6:30 PM EDT until April 13, 2007, and may be accessed at 888-286-8010 (domestic) or 617-801-6888 (international), with access code 68668590.
About OrthoLogic
OrthoLogic is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served conditions. The Company is focused on the development and commercialization of two product platforms: Chrysalin(r) (TP508) and AZX100.
Chrysalin, the Company's novel synthetic 23-amino acid peptide, is being studied in two lead indications, both of which represent areas of significant unmet medical need -- fracture repair and diabetic foot ulcer healing. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become a leading company in bone and tissue repair. The Company owns exclusive worldwide rights to Chrysalin.
AZX100 is a novel synthetic pre-clinical 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation called Intracellular Actin Relaxing Molecules, or ICARMs(tm). AZX100 is currently being evaluated for medically and commercially significant applications, such as prevention of keloid scarring, treatment of vasospasm associated with subarachnoid hemorrhage, and treatment of asthma. OrthoLogic has an exclusive worldwide license to AZX100.
OrthoLogic's corporate office is in Tempe, Arizona. For more information, please visit the Company's website: www.orthologic.com.